Our Impact
Since 2008, ANZUP has been dedicated to improving the lives of people affected by bladder, kidney, testicular, penile, and prostate cancers.
We proudly collaborate with a multidisciplinary network of more than 2,700+ experts across Australia, New Zealand, and around the world, leading independent, investigator-driven research that is shaping the future of cancer care.
Our clinical trials are at the heart of what we do. By testing new approaches and generating high-quality evidence, we improve treatments and outcomes for people living with “below the belt” cancers. These trials also provide access to new and promising therapies, along with a level of care and support that may not otherwise be available.
The impact of our research is real and lasting. Our findings have helped shape standards of care, influence clinical practice, and improve survival and quality of life for patients locally and globally.
Impact at a glance
- 2,700+ researchers and healthcare professionals in our network
- 39 clinical trials conducted since 2008
- 10,000+ patients enrolled in ANZUP trials
- 298 trial sites across Australia, New Zealand, and internationally
Recent research highlights:
- A new combination treatment approach for people affected by muscle invasive bladder cancer. (PCR-MIB)
- A new combination therapy with a drug that is used in the treatment of osteoporosis with immunotherapy to fight kidney cancer. (KEYPAD)
- Over 2,500 participants enrolled in a registry that will advance the understanding of Germ Cell Tumours. (iTESTIS)
- The first study of its kind to show a clear benefit of the radioligand therapy LuPSMA followed by chemotherapy in advanced hormone sensitive prostate cancer. (UpFrontPSMA)
- A new combination treatment approach that improved overall survival and quality of life for people diagnosed with high-risk hard-to-treat advanced (metastatic) prostate cancer. (ENZA-p)
- Progress towards advancing non-invasive kidney cancer care through patient-centred resources. (OAK)
- A new blood-based biomarker for predicting response to treatment. (TheraP translational research)
- An exciting new three-year partnership with Prostate Cancer Foundation of Australia (PCFA) building on our long standing relationship that will fuel advancements needed to change the lives of those affected by prostate cancer